**Synthesis and Antifungal Activity of New Heterocyclic Compounds**

Yeni Heterosiklik Bileşiklerin Sentezleri ve Antifungal Etkileri

Zafer Asım Kaplancıklı1,2, Mehlika Dilek Altıntop2, Gülhan Turan-Zitouni2, Ahmet Özdemir2, Rasime Demirel3, Usama Abu Mohsen4, Weiam Hussein1

1Anadolu University, Graduate School of Health Sciences, 2Pharmacy, ESKİŞEHİR
3 Anadolu University, Faculty of Science, Eskişehir, Turkey
4 Al-Azhar University, Faculty of Pharmacy, Gaza, Palestine


**ABSTRACT**

**Purpose:** The objective of this study was to describe the synthesis of 2-arylthio-N-(2-methoxydibenzo[b,d]furan-3-yl)acetamide derivatives as heterocyclic compounds and focused on their potential antifungal effects against fungi species.

**Method:** The reaction of 2-chloro-N-(2-methoxydibenzo[b,d]furan-3-yl)acetamide with various aromatic thiols gave 2-arylthio-N-(2-methoxydibenzo[b,d]furan-3-yl)acetamide derivatives. Antifungal activities of the synthesized compounds have been evaluated using microbroth dilution method.

**Results:** Four new heterocyclic compounds were synthesized. All compounds were as effective as ketoconazole against T. harzianum, A. ochraceus, C. albicans, whilst the compounds were more effective than ketoconazole against F. solani, F. moniliforme, F. culmorum.

**Conclusion:** All synthesized compounds had significant antifungal activity when compared with ketoconazole.

**Key Words:** Antifungal activity, Microbroth dilution method, Dibenzo[b,d]furan, Heterocyclic compound.

**ÖZET**

**Amaç:** Bu çalışmanın amacı, heterosiklik bileşik olarak, 2-arylthio-N-(2-metoksidibenzo[b,d]furan-3-yl)asetamid türevlerinin sentezleri ve mantar türlerine karşı etkilerini araştırmaktır.

**Yöntem:** 2-Kloro-N-(2-metoksidibenzo[b,d]furan-3-yl)asetamid ile uygun aromatik tiyollerin reaksiyonu 2-arylthio-N-(2-metoksidibenzo[b,d]furan-3-yl)asetamid türevlerini verdi. Sentezlenen bu bileşiklerin antifungal aktiviteleri microbroth dilution method kullanılarak araştırıldı.

**Bulgular:** Dört yeni heterosiklik bileşik sentezlendi. Bileşiklerin tamamı F. solani, F. moniliforme, F. culmorum’a karşı Ketokonazol’den daha aktif çıkarken, C. albicans, T. harzianum, A. ochraceus’e karşı Ketokonazol ile aynı etkiye göstermiştir.

**Sonuç:** Ketokonazol ile kıyaslandığında, sentezlenen tüm bileşikler önemli derecede antifungal etki göstermişlerdir.

**Anahtar Kelimeler:** Antifungal aktivite, Microbroth dilution method, Dibenzo[b,d]furan, Heterosiklik bileşik.
INTRODUCTION

Invasive fungal infections are becoming increasingly implicated as a cause of crucial and fatal diseases. This is especially the case in immunocompromised patients, who have a tendency to infections caused by opportunistic fungal pathogens that are normally kept in check by a functioning immune system. Antifungal therapies for curative, pre-emptive or prophylactic intentions have been developed to overcome the threat of fungal infection, but have also led to the development of resistance to the currently available antifungal agents1,2,3.

As known, not only biochemical similarity of the human cell and fungi forms is a handicap for selective activity, but also the easily gained resistance is the main problem encountered in developing safe and effective antifungals. The incidence of systemic fungal infections has been increasing. The choice of suitable antifungal agents remains relatively limited, although the advent of the new echinocandin class is a welcome development as the expansion of members of the azole antifungals as heterocyclic compounds4,5,6.

There are two basic approaches to develop a new antifungal drug: (i) synthesis of analogues, modifications or derivatives of existing compounds for shortening and improving fungal infection treatment and, (ii) searching novel structures, that the fungus organisms have never been presented with before, for the treatment of fungal infection7.

To pursue this goal, our research efforts are directed to finding new chemical classes of antifungal agents. The methods of investigation using structure–activity relationships (SAR) enabled us to find some new pharmacophores of the above-mentioned activity. Many studies have been carried out on heterocyclic systems bearing an arylthio group as a pharmacophore8,9,10.

In view of this data, we aimed at the synthesis and antifungal evaluation of new arylthio-dibenzofuran derivatives.

MATERIAL and METHOD

General procedure for the synthesis of the compounds

2-Chloro-N-(2-methoxydibenzo[b,d]furan-3-yl)acetamide (1)

Chloroacetyl chloride (0.1 mol) was added dropwise with stirring to a mixture of 3-amino-2-methoxydibenzofuran (0.1 mol) and triethylamine in toluene at 0-5°C. The solvent was evaporated under reduced pressure. The residue was washed with water and crystallized from ethanol11.

2-Arylthio-N-(2-methoxydibenzo[b,d]furan-3-yl)acetamide derivatives (2a-d)

A mixture of 2-chloro-N-(2-methoxydibenzo[b,d]furan-3-yl)acetamide (2 mmol) and aromatic thiol (2 mmol) in acetone (10 mL) was stirred at room temperature for 8 hours in the presence of potassium carbonate (2 mmol) and filtered. The residue was washed with water and crystallized from ethanol.
Microbiology

Anticandidal activity

The antimicrobial activities of the compounds were tested using the microbroth dilution method\textsuperscript{12}. Tested microorganism strain was Candida albicans (ATCC-22019). Microbroth dilution-susceptibility assay was used for antimicrobial evaluation of the compounds. Stock solutions of the samples were prepared in dimethyl sulfoxide. Dilution series using sterile distilled water were prepared from 4 mg/mL to 0.0039 mg/mL in micro-test tubes that were transferred to 96-well microtiter plates. Overnight-grown C. albicans suspension in double-strength Mueller–Hinton broth was standardized to 108 CFU/mL using McFarland No: 0.5 standard solutions. Hundred microliter of C. albicans suspension in double-strength Mueller–Hinton broth was standardized to 108 CFU/mL using McFarland No: 0.5 standard solutions. Hundred microliter of C. albicans suspension was then added into the wells. The last well-chain without a microorganism was used as a negative control. Sterile distilled water and the medium served as a positive growth control. After incubation at 37°C for 18-24 h, antimicrobial activity was detected by spraying of 0.5% TTC (2,3,5-triphenyl tetrazolium chloride, Merck) aqueous solution. MIC was defined as the lowest concentration of compounds that inhibited visible growth, as indicated by the TTC staining. Ketoconazole was used as standard antifungal agent.

Antifungal activity against molds

The antifungal activities of the compounds against molds were tested using the microbroth dilution method with some modifications\textsuperscript{12,13}. Tested mold strains were Aspergillus parasiticus (NRRL 465), Penicillium chrysogenum (NRRL 1951), Trichoderma harzianum (NRRL 20565), Aspergillus ochraceus (NRRL 3174), Fusarium solani (NRRL-13414), Fusarium moniliforme (NRLL 1866), Fusarium culmorum (wild culture). Fungal strains grown on PDA at 25°C for 5 suspensions in double-strength Potato Dextrose Broth (PDB) were standardized to 105 spores/mL. Hundred microliter of each spore suspension was then added into the wells. The last well-chain without a fungus was used as a negative control. Sterile distilled water and the medium served as a positive growth control. After incubation at 25°C for
48-72 h, antifungal activity was detected by investigation of mycelia growing under stereo microscope. Minimum fungicidal concentration (MFC) was defined as the lowest concentration of compounds that inhibited visible mycelia growth. Ketoconazole was used as an antifungal agent.

Table 1. Antifungal activity (MFC) of the compounds (µg/mL)

<table>
<thead>
<tr>
<th>Compound</th>
<th>A</th>
<th>B</th>
<th>C</th>
<th>D</th>
<th>E</th>
<th>F</th>
<th>G</th>
<th>H</th>
</tr>
</thead>
<tbody>
<tr>
<td>2a</td>
<td>250</td>
<td>250</td>
<td>250</td>
<td>250</td>
<td>250</td>
<td>250</td>
<td>250</td>
<td>250</td>
</tr>
<tr>
<td>2b</td>
<td>250</td>
<td>125</td>
<td>250</td>
<td>250</td>
<td>250</td>
<td>250</td>
<td>250</td>
<td>250</td>
</tr>
<tr>
<td>2c</td>
<td>250</td>
<td>250</td>
<td>250</td>
<td>250</td>
<td>250</td>
<td>250</td>
<td>250</td>
<td>250</td>
</tr>
<tr>
<td>2d</td>
<td>250</td>
<td>250</td>
<td>250</td>
<td>250</td>
<td>250</td>
<td>250</td>
<td>250</td>
<td>250</td>
</tr>
<tr>
<td>Ketoconazole</td>
<td>125</td>
<td>7.8</td>
<td>250</td>
<td>250</td>
<td>500</td>
<td>500</td>
<td>500</td>
<td>250</td>
</tr>
</tbody>
</table>

A: A. parasiticus (NRRL 465), B: P. chrysogenum (NRRL 1951), C: T. harzianum (NRRL 20565), D: A. ochraceus (NRRL 3174), E: F. solani (NRRL-13414), F: F. moniliforme (NRRL 1866), G: F. culmorum (wild culture), H: C. albicans (ATCC-22019)

RESULTS

2-Arylthio-N-(2-methoxydibenzo[b,d]furan-3-yl)acetamide derivatives were synthesized via the reaction of 2-chloro-N-(2-methoxydibenzo[b,d]furan-3-yl)acetamide with aromatic thiols. The structures of compounds 2a-2d were confirmed by 1H-NMR, mass spectral data and elemental analysis. The general structure of the compounds is given in Figure 1.

All compounds were tested in vitro against A. parasiticus, P. chrysogenum, T. harzianum, A. ochraceus, F. solani, F. moniliforme, F. culmorum, C. albicans. Observed data on the antifungal activity of the compounds and control drug are given in Tables 1.

DISCUSSION

All compounds showed significant antifungal activity against C. albicans. The compounds and ketoconazole showed the inhibitory activity against C. albicans with a MFC value of 250 µg/mL.

All compounds were as effective as ketoconazole against T. harzianum, A. ochraceus, whilst the compounds were more effective than ketoconazole against F. solani, F. moniliforme, F. culmorum. All compounds showed the inhibitory activity against Fusarium species with a MFC value of 250 µg/mL.

CONCLUSION

All compounds had significant antifungal activity. It is worthwhile to extend the bioactivity evaluation from in vitro whole cells to a mechanistic enzymatic level as well as to further in vivo studies. In future research, the cytotoxic effects of the compounds can also be investigated.

REFERENCES


Yazışma Adresi / Address for Correspondence:
Dr. Zafer Asım Kaplancıklı
Anadolu University
Graduate School of Health Sciences
ESKİŞEHİR
e-mail: zakaplan@anadolu.edu.tr.

geliş tarihi/received: 11.07.2012
kabul tarihi/accepted: 07.09.2012